Hemogenyx Pharmaceuticals (LSE:HEMO) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals 3-Year EBITDA Growth Rate?

Hemogenyx Pharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was £-0.00.

During the past 5 years, the average EBITDA Per Share Growth Rate was 0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hemogenyx Pharmaceuticals was 17.80% per year. The lowest was -10.10% per year. And the median was 9.10% per year.

Competitive Comparison of Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Hemogenyx Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Hemogenyx Pharmaceuticals (LSE:HEMO) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Hemogenyx Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines